In contrast, T4 does not compete with steroids for the binding site on ER, but instead T4 activates MAPK to phosphorylate ER and thus we anticipated that tamoxifen would not oppose the proliferative action of T4 in ER-positive breast cancer. The gene discussed is CD4; the disease is breast carcinoma.